Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E34.38 EPS (ttm)1.71 Insider Own0.10% Shs Outstand1.67B Perf Week-0.84%
Market Cap98.16B Forward P/E19.40 EPS next Y3.03 Insider Trans-21.05% Shs Float1.50B Perf Month-21.45%
Income2.87B PEG1.76 EPS next Q0.64 Inst Own74.30% Short Float0.64% Perf Quarter-17.61%
Sales17.62B P/S5.57 EPS this Y-22.30% Inst Trans-0.10% Short Ratio1.02 Perf Half Y-7.47%
Book/sh8.93 P/B6.58 EPS next Y15.13% ROA9.00% Target Price68.75 Perf Year-0.80%
Cash/sh2.78 P/C21.11 EPS next 5Y19.59% ROE19.60% 52W Range55.04 - 77.12 Perf YTD-13.62%
Dividend1.52 P/FCF- EPS past 5Y-12.20% ROI4.60% 52W High-24.96% Beta0.58
Dividend %2.59% Quick Ratio1.40 Sales past 5Y-3.20% Gross Margin75.70% 52W Low5.14% ATR1.46
Employees25000 Current Ratio1.60 Sales Q/Q17.00% Oper. Margin20.80% RSI (14)24.65 Volatility1.68% 2.09%
OptionableYes Debt/Eq0.45 EPS Q/Q990.60% Profit Margin16.30% Rel Volume1.15 Prev Close58.76
ShortableYes LT Debt/Eq0.44 EarningsJul 28 BMO Payout87.80% Avg Volume9.49M Price57.87
Recom2.50 SMA20-6.83% SMA50-16.59% SMA200-13.65% Volume5,826,569 Change-1.51%
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Jan-15-14Reiterated Argus Buy $58 → $62
Aug-30-16 10:00AM  Spotlight (STLT) to Help Fund Breakthrough Drug Research
08:25AM  [$$] Bristol-Myers Squibb misses mark with cancer drug at Financial Times
Aug-29-16 12:26PM  Healthcare's best bets following generic EpiPen
Aug-28-16 07:07AM  Time to Shift Your Focus
Aug-25-16 06:08PM  Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo
Aug-24-16 11:04AM  How Did Bristol-Myers Squibb Fare in 2Q16?
Aug-23-16 06:59AM  Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016 Business Wire
Aug-22-16 06:15PM  Allied Minds, Bristol-Myers Squibb to progress first drug to preclinical trials at bizjournals.com
09:06AM  How Did Bristol-Myers Squibbs Oncology Segment Perform in 2Q16?
08:36AM  Bristol-Myers Squibb Stock Will Bounce Back -- Here's How You Can Profit
07:20AM  [$$] Pfizer agrees $14bn takeover of Medivation at Financial Times
12:35AM  [$$] The Profit and Peril of Cancer Drugs at The Wall Street Journal
Aug-21-16 02:11PM  5 Trade Ideas for Monday: Bank of America, Bristol-Myers, DuPont, Halliburton and Mylan
12:33PM  Curbing Excessive Exuberance May be Premature
Aug-20-16 08:07AM  These 3 Stocks Could Boost Their Dividends in the Next 12 Months at Motley Fool
Aug-19-16 05:04PM  How Does Bristol-Myers Squibbs Valuation Compare to Peers?
01:12PM  [$$] The Profit and Peril of Cancer Drugs at The Wall Street Journal
12:41PM  ETFs with exposure to Bristol-Myers Squibb Co. : August 19, 2016
Aug-18-16 04:40PM  Is It "Game Over" After Portola's FDA Rejection? at Motley Fool
Aug-17-16 10:22AM  Bristol-Myers Squibb attracts upside bets
Aug-16-16 10:11AM  Mirror Image: Bristol-Myers Loss Is Merck's Potential Gain
Aug-15-16 03:53PM  Bristol-Myers Squibb (BMY) Stock Falls, Bernstein: Failed Trial Impact to Persist
09:26AM  Bristol-Myers to Reacquire Rights to Oncology Drug in Asia
09:06AM  What Are Mercks Key Diabetes Products?
Aug-14-16 03:02PM  Bristol-Myers' Revolutionary Cancer Drug Suffers A Big Blow at Motley Fool
09:56AM  Stay the Course
07:18AM  3 Beaten-Up Big Pharma Stocks: Are They Bargains? at Motley Fool
Aug-13-16 12:01AM  [$$] 5 Safe European Stocks With Yields Up to 5% at Barrons.com
Aug-12-16 01:42PM  How Risky Is Celldex Therapeutics, Inc.? at Motley Fool
05:50AM  [$$] Samsung biopharma unit lines up South Korea IPO at Financial Times
01:00AM  AstraZeneca Transcends Brexit Woes on Pound Slump, Rivals Flop at Bloomberg
01:00AM  AstraZeneca Rides High, Fueled by Brexit, Bristol-Myers Failure
Aug-11-16 03:53PM  Will Bristol-Myers (BMY) Stock Be Hurt by Downgrade?
08:59AM  The Market In 5 Minutes: Valeant's Fraud, Macy's Beat, And Arianna's Departure
08:16AM  Berenberg Downgrades Bristol-Myers Squibb, Says Competitors Better Exposed For Near-Term Upside
07:38AM  Cramer: Valeant Probe Is a Reminder of the Bristol-Myers Scandal
07:23AM  Bristol-Myers downgraded by Berenberg
Aug-10-16 06:40PM  After Opdivo's Failure, Is Merck a Better Buy Than Bristol-Myers? at Motley Fool
11:42AM  Argus: Bristol-Myers Selloff Is Overdone, Reiterating $90 Target
09:05AM  Major Pharma Short Interest Slides at 24/7 Wall St.
05:45AM  Samsung BioLogics seeks to raise up to $2.5 billion from IPO at MarketWatch
Aug-09-16 11:49AM  Bernstein Says Merck's Lung Cancer Drug Will Lead The Market Near-Term, But Long-Term Market Share Harder To Predict
10:00AM  Don't Write Off Bristol-Myers After Opdivo Setback
08:33AM  Bristol-Myers Hit With A Trio Of Analyst Price Target Cuts
02:42AM  AstraZeneca drug selumetinib fails in lung cancer study Reuters
12:09AM  U.S. Stocks Down Despite Surge in Energy Sector at The Wall Street Journal
Aug-08-16 05:23PM  Stocks to Watch Evening Roundup: Valeant Preview, Bristol's Pain, Wal-Mart's Jet at Barrons.com
04:38PM  Taking that next step forward in your trading with sizing
04:36PM  The way you express yourself successfully in markets
04:25PM  US STOCKS-Wall Street takes tiny step back from record highs
04:03PM  Stocks Retreat From Records as Health Care Slumps
03:29PM  Stocks Lower In Afternoon Trade; Ski Resort Firm Leaps On Buyout
02:50PM  Stocks Fall as Health Care Selloff Counters Energy Rally
02:26PM  Why Dean Foods, Bristol-Myers, and Three Other Stocks Are on the Move Today at Insider Monkey
02:02PM  Energy Stocks Gain as Output Freeze Talk Bolsters Oil at The Wall Street Journal
01:18PM  [$$] Allergan setback prompts healthcare slide at Financial Times
01:05PM  Bristol-Myers: Lung Cancer Failure 'Too Significant' To Stay Bullish at Barrons.com
12:45PM  Why Credit Suisse Sees Merck and Bristol-Myers Gap Widening Further at 24/7 Wall St.
10:46AM  How Bad Does Bristol-Myers Squibb Look After Friday?
10:42AM  After Roaring To New Highs on Jobs Data, Market Faces Retail Sales, Job Openings
10:32AM  Why Merck's Lung Cancer Success Won't Last at Barrons.com
10:09AM  Bristol-Myers Squibb (BMY) Stock Slides, Credit Suisse Downgrades
10:00AM  Bristol-Myers' stock extends slide after downgrade, Merck upgraded at MarketWatch
09:24AM  Blog Coverage Announced for Bristol Myers
08:55AM  Top Analyst Upgrades and Downgrades: BlackRock, Bristol-Myers, Level 3, NVIDIA, Monsanto, 21st Century Fox and More at 24/7 Wall St.
08:46AM  4 Big-Volume Stocks to Add to Your Buy List -- Plus 3 to Avoid
08:25AM  Bristol-Myers Squibb Co. breached its 50 day moving average in a Bearish Manner : BMY-US : August 8, 2016
08:16AM  Morning Movers: MFRM, DAL, AMZN, BMY
Aug-07-16 08:37PM  Bristol-Myers Partner Ono Plunges as Drug Fails Trial at Bloomberg
08:30PM  What Next for Bristol-Myers and Merck?
09:15AM  Lets Get Real!
Aug-06-16 12:07PM  Why Bristol-Myers lung-cancer drug could still succeed despite stunning trial failure at MarketWatch
12:26AM  [$$] How Bristol-Myers Survives a Failure at The Wall Street Journal
12:25AM  Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study at The Wall Street Journal
Aug-05-16 08:59PM  Takeaways, Observations and Tesla: Best of Kass -15.99%
05:13PM  Top trades: Netflix, Bristol-Meyers & more
05:11PM  Stocks to Watch Evening Roundup: Bristol-Myers' Failure, Kraft Heinz's Beat, Regeneron's Cut at Barrons.com
04:59PM  Bristol-Myers Investors Feel the Harsh Downside of Cancer Bet at Bloomberg
04:49PM  Bristol-Myers Plunges On Surprise Opdivo Failure In Lung Cancer
04:37PM  Bristol-Myers drug fails lung cancer study, shares plunge
04:24PM  Bristol-Myers Squibb (BMY) Stock Downgraded at Morgan Stanley
03:16PM  Analyst: Definite 1- to 2-year setback for Bristol
03:13PM  Stocks Rally, On Track For Weekly Gain, As Apple, Merck Lead The Dow
03:12PM  Bristol-Myers Squibb (BMY) Stock Shouldn't Be So Low, Guggenheim's Butler Tells CNBC
02:50PM  Bristol-Myers Tanks, Buy These Two Large Cap Pharma Stocks Instead
02:07PM  Pharma's big movers
01:49PM  Bristol-Myers: All Is Not Lost at Barrons.com
01:40PM  Shares of Bristol-Myers Falling After Failed Study, While Its Rival Is Surging
01:07PM  Merck's tremendous, awesome, really good day
01:04PM  BMY's very bad, horrible, awful day
12:27PM  Buy Bristol-Myers on the dip?
12:20PM  Stocks Rise After Upbeat Jobs Data
12:18PM  Cramer says he's shocked like everyone else on Bristol-Myers drug results at CNBC
12:00PM  Merck Could Gain from Bristol's Poor Drug Trial Results
11:16AM  Stocks Roar On Jobs Report; Priceline, Merck Break Out
11:07AM  [$$] How Bristol-Myers Survives a Failure at The Wall Street Journal
11:03AM  Bristol-Myers Squibb: A $4 Billion Disaster at Barrons.com
11:00AM  Bristol-Myers stock gets slammed after failed drug test
10:35AM  Why Bristol-Myers Failure Is a Huge Win for Merck at 24/7 Wall St.
10:31AM  More Squawk From Jim Cramer: 'Astonished' That Bristol Myers (BMY) Drug Failed
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDREOTTI LAMBERTODirectorAug 25Sale58.9211,600683,472345,299Aug 25 05:10 PM
ANDREOTTI LAMBERTODirectorAug 24Sale59.4311,600689,359356,899Aug 25 05:10 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,511015,250Aug 03 04:56 PM
ANDREOTTI LAMBERTODirectorJul 08Sale75.0411,600870,461368,499Jul 11 05:12 PM
ANDREOTTI LAMBERTODirectorJul 07Sale73.8611,600856,776380,099Jul 11 05:12 PM
Blin EmmanuelSVP, Chief Strategy OfficerJul 02Option Exercise0.00951012,516Jul 06 05:58 PM
Cuss Francis MEVP & CSOJul 01Option Exercise0.003,6550291,628Jul 06 05:58 PM
Gordon MurdoEVP, Chief Commercial OfficerJul 01Option Exercise0.002,335014,950Jul 06 05:58 PM
ANDREOTTI LAMBERTODirectorJun 29Sale72.799,800713,342392,194Jun 30 05:42 PM
ANDREOTTI LAMBERTODirectorJun 28Sale71.6713,400960,396390,394Jun 30 05:42 PM
Elicker John ESVP, Public Affairs & IRJun 14Sale72.6911,820859,21955,011Jun 16 04:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMay 20Sale70.7930,2012,137,838184,694May 24 05:04 PM
Caldarella Joseph CSVP & ControllerMay 16Sale72.473,519255,00455,238May 17 04:46 PM
Caforio GiovanniChief Executive OfficerMay 05Option Exercise0.008,0400134,549May 09 04:42 PM
Caforio GiovanniChief Executive OfficerMay 03Option Exercise24.7950,4551,250,602145,958May 05 04:31 PM
Caforio GiovanniChief Executive OfficerMay 03Sale71.3134,5942,466,885117,118May 05 04:31 PM
ANDREOTTI LAMBERTODirectorMay 02Option Exercise26.04234,7206,112,787671,514May 04 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyMay 02Sale71.9522,2181,598,65221,971May 04 05:28 PM
ANDREOTTI LAMBERTODirectorMay 02Sale71.88234,72016,870,792436,794May 04 05:28 PM
ANDREOTTI LAMBERTODirectorApr 05Sale66.0011,600765,626436,794Apr 06 04:18 PM
ANDREOTTI LAMBERTODirectorApr 04Sale65.7911,600763,216448,394Apr 06 04:18 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554025,260Apr 05 04:59 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0031,624055,059Mar 14 09:44 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0037,1430300,492Mar 14 09:43 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00204,4470574,101Mar 14 09:43 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,860074,177Mar 14 09:43 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0020,460067,864Mar 14 09:44 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,406089,478Mar 14 09:42 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0060,6230132,906Mar 14 09:42 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0057,4840366,730Mar 14 09:42 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,435032,069Mar 14 09:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.008,806059,091Mar 14 09:41 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0075,6180247,158Mar 14 09:41 PM
Blin EmmanuelSVP, Head of CommercializationMar 10Option Exercise0.0011,707013,498Mar 14 09:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 10Option Exercise0.0019,309019,608Mar 14 09:41 PM
CAMPBELL LEWIS BDirectorMar 08Option Exercise24.962,50062,4002,500Mar 10 04:36 PM
CAMPBELL LEWIS BDirectorMar 08Sale66.002,500165,0000Mar 10 04:36 PM
Caforio GiovanniChief Executive OfficerMar 06Option Exercise0.002,889079,627Mar 08 04:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 06Option Exercise0.001,28202,611Mar 08 04:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724050,821Mar 08 04:43 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931048,253Mar 08 04:43 PM
LEUNG SANDRAEVP, General CounselMar 06Option Exercise0.005,5740315,121Mar 08 04:41 PM
Elicker John ESVP, Public Affairs & IRMar 06Option Exercise0.001,043053,715Mar 08 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100269,043Mar 08 04:42 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,391060,032Mar 08 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3240169,885Mar 08 04:40 PM
Blin EmmanuelSVP, Head of CommercializationMar 06Option Exercise0.0081901,553Mar 08 04:41 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528024,746Mar 08 04:40 PM
Caldarella Joseph CSVP & ControllerMar 04Sale64.6412,962837,91646,322Mar 07 05:41 PM
Caforio GiovanniChief Executive OfficerFeb 17Option Exercise22.8920,125460,66188,778Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Option Exercise22.7314,560330,949319,699Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Sale63.5710,152645,342309,547Feb 19 04:32 PM
Caforio GiovanniChief Executive OfficerFeb 17Sale63.5812,040765,52776,738Feb 19 04:32 PM
ANDREOTTI LAMBERTODirectorFeb 04Option Exercise0.00148,1800445,820Feb 08 04:31 PM
Paliwal Dinesh CDirectorFeb 01Option Exercise0.003,25703,257Feb 03 06:28 PM
ANDREOTTI LAMBERTODirectorJan 05Sale68.1911,600791,028310,424Jan 06 04:40 PM
ANDREOTTI LAMBERTODirectorJan 04Sale66.9311,600776,332322,024Jan 06 04:40 PM
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00950053,012Jan 05 06:21 PM
ANDREOTTI LAMBERTODirectorDec 15Sale70.0511,600812,580332,852Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorDec 14Sale68.0011,600788,843344,452Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorNov 20Sale67.7611,600786,016501,052Nov 23 04:41 PM
ANDREOTTI LAMBERTODirectorNov 19Sale67.0211,600777,470512,652Nov 23 04:41 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000163,957Nov 03 03:45 PM
Elicker John ESVP Pub Affairs & Inv RelationNov 01Option Exercise0.00496052,286Nov 03 03:45 PM
ANDREOTTI LAMBERTODirectorOct 06Sale59.7311,600692,904524,252Oct 08 04:08 PM
ANDREOTTI LAMBERTODirectorOct 05Sale61.9911,600719,027535,852Oct 08 04:08 PM
ANDREOTTI LAMBERTODirectorSep 03Sale59.5711,600691,032546,874Sep 03 06:34 PM
ANDREOTTI LAMBERTODirectorSep 02Sale59.2211,600687,005558,474Sep 03 06:34 PM